viewRedx Pharma PLC

Redx Pharma appoints CFO as it publishes annual results

Dr James Mead joins the life sciences company on February 1

boardroom table
Redx will have a new face around the boardroom table

Redx Pharma Plc (LON:REDX) pharma announced the appointment of a new chief financial officer at the same as presenting its figures for the last financial year.

Dr James Mead, who has held senior roles at AstraZeneca, will take over from interim incumbent Dominic Jackson on February 1.

READ: Redx Pharma hails new fibrosis drug candidate

"I am delighted to have James join our team at Redx. He will bring a dynamic and professional approach and will play an integral role as we focus on progressing delivery of our strategy,” said chief executive Lisa Anson.

The 41-year-old joins the business at an exciting. Having defined a new strategy under the guidance chairman Iain Ross after a period in administration, Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Treatments for cancer and fibrosis 

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Financially, the benchmark for small drug discovery groups such as Redx is cash in the bank. As at the period-end it had £6.5mln, the equivalent of three-quarters of the company’s current market capitalisation.

As is common for businesses at this early stage of development, Redx was loss-making. The deficit for the year ended September 30 was £8.8mln, with operating expenditure reduced £5.2mln to £10.6mln.

Chairman Ross said: "This set of results confirms that Redx is operationally a stronger and leaner company led by an ambitious new management team, with a clear strategic direction. 

“Lisa Anson has made a major impact and under her leadership, the group is starting to make real progress in our programmes aimed at creating high-value drugs that treat significant unmet need in cancer and fibrosis.”

Quick facts: Redx Pharma PLC

Price: 57.5 GBX

Market: AIM
Market Cap: £112.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...


Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

on 4/8/20

2 min read